Allogene Therapeutics Inc
ALLO1.210USD
+0.080+7.08%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
266.36MMarket Cap
LossP/E TTM
More Details of Allogene Therapeutics Inc Company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Company Info
Ticker SymbolALLO
Company nameAllogene Therapeutics Inc
IPO dateOct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
Number of employees226
Security typeOrdinary Share
Fiscal year-endOct 11
Address210 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504572700
Websitehttps://allogene.com/
Ticker SymbolALLO
IPO dateOct 11, 2018
CEODr. David D Chang, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
--
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
--
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Mr. Earl Martin Douglas, Esq.
Mr. Earl Martin Douglas, Esq.
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
110.21K
-5.49%
Dr. Zachary Roberts, M.D., Ph.D.
Dr. Zachary Roberts, M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
101.90K
-38.68%
Ms. Deborah M. (Debbie) Messemer
Ms. Deborah M. (Debbie) Messemer
Independent Director
Independent Director
45.96K
-44.53%
Mr. Todd B. Sisitsky
Mr. Todd B. Sisitsky
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
--
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.72M
--
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
478.17K
-0.90%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
218.51K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pfizer Inc
9.93%
TPG Capital, L.P.
8.44%
Citadel Advisors LLC
6.01%
BlackRock Institutional Trust Company, N.A.
5.10%
Capital World Investors
5.03%
Other
65.50%
Shareholders
Shareholders
Proportion
Pfizer Inc
9.93%
TPG Capital, L.P.
8.44%
Citadel Advisors LLC
6.01%
BlackRock Institutional Trust Company, N.A.
5.10%
Capital World Investors
5.03%
Other
65.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.36%
Hedge Fund
16.70%
Private Equity
13.98%
Corporation
10.45%
Investment Advisor/Hedge Fund
9.91%
Individual Investor
6.98%
Research Firm
4.02%
Venture Capital
0.82%
Sovereign Wealth Fund
0.12%
Other
8.65%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
408
225.96M
103.31%
-7.24M
2025Q1
437
219.29M
100.27%
-22.18M
2024Q4
434
209.87M
100.10%
-25.68M
2024Q3
441
205.03M
101.51%
-25.11M
2024Q2
447
205.90M
102.27%
+9.93M
2024Q1
446
170.59M
100.21%
-14.52M
2023Q4
455
160.71M
95.67%
-29.40M
2023Q3
461
177.28M
107.46%
-30.31M
2023Q2
461
179.96M
123.50%
-2.72M
2023Q1
465
163.54M
112.33%
-14.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pfizer Inc
22.03M
10.07%
--
--
Mar 31, 2025
TPG Capital, L.P.
18.72M
8.56%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.20M
4.66%
+4.85M
+90.75%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.81M
4.94%
-33.81K
-0.31%
Mar 31, 2025
Capital World Investors
12.27M
5.61%
+5.37M
+77.85%
Mar 31, 2025
Lynx1 Capital Advisors LLC
11.06M
5.06%
+182.29K
+1.68%
Mar 31, 2025
Darwin Global Management Ltd
10.45M
4.78%
+10.45M
--
Mar 31, 2025
The Vanguard Group, Inc.
8.07M
3.69%
+91.07K
+1.14%
Mar 31, 2025
Belldegrun (Arie S)
7.56M
3.46%
-282.53K
-3.60%
Mar 31, 2025
Chang (David D)
5.72M
2.62%
-461.70K
-7.46%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
WisdomTree BioRevolution Fund
0.78%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Global X Genomics & Biotechnology ETF
0.21%
Zacks Small/Mid Cap ETF
0.14%
iShares Health Innovation Active ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
JPMorgan Fundamental Data Science Small Core ETF
0.03%
iShares Biotechnology ETF
0.02%
View more
WisdomTree BioRevolution Fund
Proportion0.78%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.73%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
Global X Genomics & Biotechnology ETF
Proportion0.21%
Zacks Small/Mid Cap ETF
Proportion0.14%
iShares Health Innovation Active ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
